Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis - Archive ouverte HAL
Article Dans Une Revue Médecine et Maladies Infectieuses Année : 2020

Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis

Résumé

Purpose Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor. Patients and method We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database. Results Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation. Conclusion Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.
Fichier principal
Vignette du fichier
S0399077X20306739.pdf (296.42 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03492593 , version 1 (07-11-2022)

Licence

Identifiants

Citer

Julia Brochard, Florent Morio, Julien Mahe, Patrice Le Pape, T. Guimard, et al.. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis. Médecine et Maladies Infectieuses, 2020, 50, pp.742 - 745. ⟨10.1016/j.medmal.2020.07.005⟩. ⟨hal-03492593⟩
52 Consultations
41 Téléchargements

Altmetric

Partager

More